4.7 Article

Small Molecule CCR4 Antagonists Protect Mice from Aspergillus Infection and Allergy

Journal

BIOMOLECULES
Volume 11, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/biom11030351

Keywords

CCR4; Aspergillus fumigatus; vaccine; cystic fibrosis; invasive aspergillosis; allergic bronchopulmonary aspergillosis

Funding

  1. European Community's Seventh Framework Programme (FP7/2007-2013) [260338]
  2. Specific Targeted Research Project FunMeta [ERC-2011-AdG-293714]
  3. Agence Nationale de la Recherche, France [ANR-19-CE17-0021(BASIN)]

Ask authors/readers for more resources

The study assessed the potential therapeutic efficacy of a CCR4 small molecule antagonist against various settings of fungal infection, demonstrating effectiveness in different scenarios. The results suggest the need for developing novel compounds with potential for clinical trials in the field of CCR4 antagonism.
The ability to regulate the recruitment of immune cells makes chemokines and their receptors attractive drug targets in many inflammatory diseases. Based on its preferential expression on T helper type 2 (Th2) cells, C-C chemokine receptor type 4 (CCR4) has been widely studied in the context of allergic diseases, but recent evidence on the expression of CCR4 in other cell types has considerably expanded the potential applications of CCR4 antagonism. However, the current number of approved indications, as well as the portfolio of CCR4-targeting drugs, are still limited. In the present study, we have assessed the potential therapeutic efficacy of a CCR4 small molecule antagonist, SP50, discovered via an in silico-based approach, against a variety of pre-clinical settings of infection with the fungus Aspergillus fumigatus. We show that SP50 efficiently worked as prophylactic vaccine adjuvant in immunocompetent mice, protected against invasive aspergillosis in immunosuppressed mice. Further, the CCR4 antagonist prevented allergic bronchopulmonary aspergillosis in susceptible mice, and in a murine model of cystic fibrosis, a genetic disorder characterized by chronic pulmonary inflammation and recurrent infections. In conclusion, our results extend the potential applications of CCR4 antagonism and prompt for the development of novel compounds with the potential to progress to clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available